Register

Hematology

NCI-CCC Tumor Board Question   

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?
1 Answer available
What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?
1 Answer available
How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?
1 Answer available
How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?
1 Answer available
Would you recommend allogeneic stem cell transplantation for consolidation in a patient with follicular lymphoma who relapsed within 13 months of initial chemo-immunotherapy?  
2 Answers available
What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?
1 Answer available
How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?
1 Answer available
How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?
0 Answers available
How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?
1 Answer available
For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?
1 Answer available
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
2 Answers available
Which patients with smoldering myeloma do you treat?
2 Answers available
How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
2 Answers available
How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?
Ki67  = 90% with multiple small nodes on PET scan and normal CBC
1 Answer available
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
2 Answers available
What's the optimal management of stage IA nodal ATLL in a young fit patient?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
1 Answer available


Papers discussed in this category

Lancet, 2019 Jun 03
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Blood,
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Haematologica, 2021 Jun 01
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Outcome of deferred initial therapy in mantle-cell lymphoma.
The New England journal of medicine, 2015-11-05
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Haematologica, 2018 May 24
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.
Blood,
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Leukemia, 2011 Jul 01
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Haematologica, 2019 Sep 19
mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Blood, 2017 Aug 17
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood, 2015 May 28
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Blood Cancer J, 2021 Jan 11
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
N Engl J Med,
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Blood cancer journal, 2018-06-12
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
J. Clin. Oncol., 2019 Oct 25
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
JAMA Oncol,
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
British journal of haematology, 2014-06
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
International journal of radiation oncology, biology, physics, 2019-06-01
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Blood, 2018-07-05
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood,
Getting to transplant in Hodgkin lymphoma: BVB.
Blood,
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
British journal of haematology, 2017-11
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
J Clin Oncol, 2016 Feb 29
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Lancet Haematol, 2016 Dec 05
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Lancet Oncol, 2022 Jan 21
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
N Engl J Med,
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Lancet Haematol,
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Leukemia, 2020 Jul 21
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Related Topics in Hematology

Copyright © 2025 theMednet
All Rights Reserved.